Phase II study of pazopanib in combination with paclitaxel in patients with metastatic melanoma
Author:
Funder
GlaxoSmithKline
Novartis Pharma
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology
Link
http://link.springer.com/article/10.1007/s00280-018-3624-6/fulltext.html
Reference32 articles.
1. Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2017. CA Cancer J Clin 67:7–30
2. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N et al (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19:3622–3634
3. Heppt MV, Dietrich C, Graf SA, Ruzicka T, Tietze JK, Berking C (2016) The systemic management of advanced melanoma in 2016. Oncol Res Treat 39:635–642
4. Long GV, Weber JS, Infante JR, Kim KB, Daud A, Gonzalez R, Sosman JA, Hamid O, Schuchter L, Cebon J, Kefford RF, Lawrence D, Kudchadkar R, Burris HA 3rd, Falchook GS, Algazi A, Lewis K, Puzanov I, Ibrahim N, Sun P, Cunningham E, Kline AS, Del Buono H, McDowell DO, Patel K, Flaherty KT (2016) Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib. J Clin Oncol 34(8):871–878
5. Flaherty K, Davies MA, Grob JJet al (2016) Genomic analysis and 3-y efficacy and safety update of COMBI-d: a phase 3 study of dabrafenib (D) + trametinib (T) vs D monotherapy in patients (pts) with unresectable or metastatic BRAF V600E/K-mutant cutaneous melanoma. J Clin Oncol 34:9502–9502 (suppl; abstr 9502)
Cited by 15 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. VEGF/VEGFR axis and its signaling in melanoma: Current knowledge toward therapeutic targeting agents and future perspectives;Life Sciences;2024-05
2. Network neighborhood operates as a drug repositioning method for cancer treatment;PeerJ;2023-07-10
3. The role of angiogenesis in melanoma: Clinical treatments and future expectations;Frontiers in Pharmacology;2022-12-15
4. Trends in Melanoma Phase 3 Clinical Trials since 2010: Is there Hope for Advanced Melanoma Therapies beyond Approved Treatment Mechanisms?;Cancers;2022-10-22
5. Melanoma Tumour Vascularization and Tissue-Resident Endothelial Progenitor Cells;Cancers;2022-08-30
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3